Download Targeting and Deconstructing the RAF Pathway in Cancer

Targeting and Deconstructing the RAF Pathway in
Cancer
Wednesday, May 25th
1 PM to 6:30 PM
Joseph B. Martin Conference Center at Harvard Medical School
The Dana Farber/Harvard Cancer Center Alliance for Developing Effective Targeted
Therapies is a new initiative, which aims to bring together basic, translational and clinical
scientists from the Harvard community. The ultimate goal of this effort is to share insight
gained from different diseases and disciplines in real time, so that we may enhance the rate
at which effective targeted cancer therapies can be developed.
Speakers:
Keith Flaherty, MGH, “Summary of the Clinical Evidence and Tumor Tissue Analyses”
Levi Garraway, DFCI, “Characterizing Resistance to RAF Inhibition in Melanoma”
David Fisher, MGH, “Lineage Specific Targets of BRAF Signaling in Melanoma”
Len Zon, CHB, “Genetics of BRAF and Melanoma in Zebrafish”
Neal Rosen, MSKCC, “Inhibiting ERK Signaling in Human Tumors: Sensitivity and Resistance”
Pasi Jänne, DFCI, “Targeting RAF/MEK/ERK in Lung Cancer”
Lynda Chin, DFCI, “Using GEM Models in Studying Response and Resistance”
A reception and Poster Session will follow the symposium.
Space is limited. Registration is required.
http://events.dfhcc.harvard.edu/
www.dfhcc.harvard.edu